Amylyx Pharmaceuticals Inc (AMLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has a cash flow conversion efficiency ratio of -0.131x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.42 Million) by net assets ($239.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AMLX market cap overview for the company's overall valuation and market capitalisation.
Amylyx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amylyx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Amylyx Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GPGI, Inc.
NYSE:GPGI
|
-0.017x |
|
Olav Thon Eien
OL:OLT
|
0.000x |
|
Societatea Energetica Electrica SA
RO:EL
|
0.070x |
|
Hinge Health, Inc.
NYSE:HNGE
|
0.169x |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
0.193x |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
|
0.144x |
|
Geovis Technology Co Ltd
SHG:688568
|
0.020x |
|
Organon & Co
NYSE:OGN
|
0.106x |
Annual Cash Flow Conversion Efficiency for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025. View latest Amylyx Pharmaceuticals Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.26 Million | $-123.34 Million | -0.404x | +60.29% |
| 2024-12-31 | $164.76 Million | $-167.65 Million | -1.017x | -3800.09% |
| 2023-12-31 | $433.43 Million | $11.92 Million | 0.027x | +105.21% |
| 2022-12-31 | $340.61 Million | $-179.87 Million | -0.528x | -206.73% |
| 2021-12-31 | $-151.17 Million | $-74.80 Million | 0.495x | -10.03% |
| 2020-12-31 | $-66.72 Million | $-36.70 Million | 0.550x | +30.49% |
| 2019-12-31 | $-25.36 Million | $-10.69 Million | 0.421x | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more